<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488980</url>
  </required_header>
  <id_info>
    <org_study_id>A-9467</org_study_id>
    <nct_id>NCT02488980</nct_id>
  </id_info>
  <brief_title>An Evaluation of Weekly Tafenoquine</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Evaluation of Weekly Tafenoquine (WR 238605/SB252263) Compared to Mefloquine for Chemosuppression of Plasmodium Falciparum in Western Kenya</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SmithKline Beecham</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a placebo controlled, randomised, double-blind, double-dummy study of the efficacy
      of weekly tafenoquine compared with weekly mefloquine or placebo in the chemosuppression of
      P. falciparum in Nyanza Province, western Kenya.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were treated for 3 days with halofantrine to clear any existing parasitaemia. At the
      end of the clearance period, subjects free from malaria parasitaemia were randomized and
      received a loading dose of the study treatment (tafenoquine 200 mg, Mefloquine 250 mg or
      placebo) for tree days, followed by study treatment (tafenoquine 200 mg, mefloquine 250 mg or
      placebo, respectively) once a week for 24 weeks. After the treatment period subjects attended
      weekly follow-up safety visits until week 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">October 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prophylactic Outcome Defined by the Subject Having no Positive Smears</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Prophylactic outcome (success/failure) at the end of the prophylactic treatment phase; outcome was based on absence/presence of asexual stage parasites of any Plasmodium species on a single blood smear.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protective Efficacy Based on Two Consecutive Positive Smears</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. Analysis was based on a calculation of protective efficacy (PE) of tefaenoquine, defined as (1-relative risk of developing parasitaemia tafenoquine: placebo) x100% and 95.5% confidence intervals were constructed for the relative risk using Koopman's method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a Single Positive Smear</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. 95.5% confidence intervals were constructed for the relative risk.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety (SAEs and AEs)</measure>
    <time_frame>28 weeks</time_frame>
    <description>The most commonly reported experiences in subject occurring in at least 20% of subjects in any treatment group.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Falciparum Parasitaemia</condition>
  <arm_group>
    <arm_group_label>Tafenoquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mefloquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafenoquine</intervention_name>
    <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
    <arm_group_label>Tafenoquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine</intervention_name>
    <description>Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
    <arm_group_label>Mefloquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for three days followed by placebo once a week for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female volunteers who provided informed consent (a healthy volunteer
             was defined as one who was free of ailments that might cause difficulty in evaluating
             drug efficacy or adverse experiences).

          -  Subjects aged 18-55 years.

          -  Subjects planning to reside in the study area for the entire study duration of
             approximately 70 weeks

        Exclusion Criteria:

          -  Subjects with positive parasitaemia following halofantrine treatment for radical cure.

          -  Subjects with any medical condition which, in the opinion of the investigator, made
             the subject unsuitable to enter the study.

          -  Subjects with personal or family history of seizures.

          -  Female subjects with a positive serum beta-HCG5 (tested during screening and within 48
             hours of first drug administration and approximately monthly thereafter).

          -  Women who were pregnant or lactating or who in the opinion of the investigator were at
             risk of becoming pregnant.

          -  Subjects with clinically significant abnormalities (to include but not limited to
             abnormal hepatic or renal function) as determined by history, physical and routine
             blood chemistries and haematology values. Subjects who had demonstrated
             hypersensitivity to any of the study drugs especially to any other 8-aminoquinolines.

          -  Subjects unwilling to report for drug administration or blood drawing during the 70
             week duration of the study.

          -  Subjects with G6PD deficiency.

          -  Subjects with laboratory guideline values for exclusion: haemoglobin &lt;10 gm/dL,
             platelets &lt;80,000/mm3, WBC &lt;3000ul3, creatinine or ALT more than twice the upper limit
             of normal for age.

          -  Subjects with an abnormal ECG, particularly an extended QTc interval &gt; 0.42 seconds.

          -  Subjects taking any other anti-malarial product, or who had taken an antimalarial drug
             other than halofantrine within the previous two weeks.

          -  Subjects who had received an investigational drug (a new chemical entity not
             registered for use) within 30 days or 5 half-lives whichever was the longer.

          -  Subjects with a history of psychiatric disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Stoute, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Hershey Infectious Diseases</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <results_first_submitted>January 5, 2017</results_first_submitted>
  <results_first_submitted_qc>January 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2017</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Falciparum Parasitaemia, Malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parasitemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mefloquine</mesh_term>
    <mesh_term>Tafenoquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>SmithKline Beecham</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at Kombewa Clinic, Kenya. 517 subjects were screened for entry in to the study. 211 of those subjects were not randomized to treatment due either to abnormal lab results, G6PD deficiency, extended QTc interval, failure to clear parasitaemia or &quot;other&quot; reason.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tafenoquine</title>
          <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
Tafenoquine: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Mefloquine</title>
          <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
Mefloquine: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo for three days followed by placebo once a week for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo for three days followed by placebo once a week for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Tafenoquine</title>
          <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
Tafenoquine: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Mefloquine</title>
          <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
Mefloquine: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prophylactic Outcome Defined by the Subject Having no Positive Smears</title>
        <description>Prophylactic outcome (success/failure) at the end of the prophylactic treatment phase; outcome was based on absence/presence of asexual stage parasites of any Plasmodium species on a single blood smear.</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo for three days followed by placebo once a week for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tafenoquine</title>
            <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
Tafenoquine: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mefloquine</title>
            <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
Mefloquine: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Prophylactic Outcome Defined by the Subject Having no Positive Smears</title>
          <description>Prophylactic outcome (success/failure) at the end of the prophylactic treatment phase; outcome was based on absence/presence of asexual stage parasites of any Plasmodium species on a single blood smear.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prophylactic Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic Success (total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic Success (known)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic Success (assumed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protective Efficacy Based on Two Consecutive Positive Smears</title>
        <description>Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. Analysis was based on a calculation of protective efficacy (PE) of tefaenoquine, defined as (1-relative risk of developing parasitaemia tafenoquine: placebo) x100% and 95.5% confidence intervals were constructed for the relative risk using Koopman's method.</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo for three days followed by placebo once a week for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tafenoquine</title>
            <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
Tafenoquine: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mefloquine</title>
            <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
Mefloquine: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Protective Efficacy Based on Two Consecutive Positive Smears</title>
          <description>Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. Analysis was based on a calculation of protective efficacy (PE) of tefaenoquine, defined as (1-relative risk of developing parasitaemia tafenoquine: placebo) x100% and 95.5% confidence intervals were constructed for the relative risk using Koopman's method.</description>
          <units>Percentage of Protective Efficacy</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="77.9" lower_limit="59.7" upper_limit="88.2"/>
                    <measurement group_id="O3" value="56.8" lower_limit="32.5" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to a Single Positive Smear</title>
        <description>Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. 95.5% confidence intervals were constructed for the relative risk.</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo for three days followed by placebo once a week for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tafenoquine</title>
            <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
Tafenoquine: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mefloquine</title>
            <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
Mefloquine: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to a Single Positive Smear</title>
          <description>Kaplan-Meier survival curves were produced for time to parasitaemia for both first positive smear and two consecutive positive smears. 95.5% confidence intervals were constructed for the relative risk.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First positive smear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="42" upper_limit="50"/>
                    <measurement group_id="O2" value="57" lower_limit="53" upper_limit="70"/>
                    <measurement group_id="O3" value="50" lower_limit="44" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two consecutive positve smears</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="57" upper_limit="79"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="165" lower_limit="154" upper_limit="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety (SAEs and AEs)</title>
        <description>The most commonly reported experiences in subject occurring in at least 20% of subjects in any treatment group.</description>
        <time_frame>28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo for three days followed by placebo once a week for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Tafenoquine</title>
            <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
Tafenoquine: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mefloquine</title>
            <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
Mefloquine: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety (SAEs and AEs)</title>
          <description>The most commonly reported experiences in subject occurring in at least 20% of subjects in any treatment group.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Respiratory Tract Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coughing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 weeks</time_frame>
      <desc>Subjects with the most frequently reported AEs (&gt;10 % of subjects in any treatment group)</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo for three days followed by placebo once a week for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Tafenoquine</title>
          <description>Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
Tafenoquine: Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Mefloquine</title>
          <description>Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
Mefloquine: Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic Anaemia</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Moniliasis GI</sub_title>
                <description>Follow-up Period</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Follow-up Period</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <description>Prophylaxis Treatment Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <description>Follow-up Period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>Follow-up Period</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="101"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="101"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="104"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="101"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="104"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="101"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="104"/>
                <counts group_id="E3" events="49" subjects_affected="49" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="101"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="104"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to high failure rate a DMC was setup to assess if it was appropriate to continue study. DMC concluded that the study should continue in order to meet secondary objectives of evaluating the long-term safety and efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jose Stoute, MD</name_or_title>
      <organization>Penn State Hershey Infectious Diseases</organization>
      <phone>800-243-1455</phone>
      <email>noemail@no.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

